Quest Diagnostics DGX Insider Ownership

NYSE DGX

$234.10 +3.64 (+1.58%)

As of: Oct 14, 2026 · 11:46 AM EDT

Insider Holdings by Owner

1.04Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.430%

▼-0.020% pp QoQ

Shares Held by Insiders

477.37K

filed for Sep 2026

▼-4.39% QoQ

Shares Outstanding

111.00Mn

111,000,000 shares

Direct Holdings

477.37K

Indirect: 0

Net Shares Traded (QoQ)

-21.93K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, DGX insiders sold $37.27 million of stock (180.01K shares) on the open market and bought none.

Counted by insider, open-market selling of DGX stock in the past 12 months came from 8 insiders, with no insider buying.
J. E. Davis (CEO and President) sold the most Quest Diagnostics stock on the open market over the past 12 months, $17.08 million (85.09K shares), most recently on September 1, 2026.
Beyond open-market trades, insiders at Quest Diagnostics received 130.4K shares in stock awards, acquired 125.69K shares through option exercises and conversions, gave up 73.35K shares to cover taxes or exercise prices and gave away 1K shares as gifts in the last 12 months.
According to Business Quant data, insiders at Quest Diagnostics reported 477.37K shares in total in their latest Form 4 filings, down 4.39% from 499.3K shares at the end of Q2 2026 and up 2.14% from 467.35K shares at the end of Q3 2025.
None of the 477.37K shares held by Quest Diagnostics insiders is held through trusts, partnerships or family members; all are direct holdings.
Business Quant counts 18 insiders with holdings in Quest Diagnostics stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
Quest Diagnostics' top three insider holders by shares held are J. E. Davis (CEO and President, 122.42K shares), Catherine T. Doherty (EVP, Regional Businesses, 67.12K shares) and Michael E. Prevoznik (SVP & General Counsel, 36.56K shares).
Of the shares held by DGX insiders, 25.65% belong to J. E. Davis.
Institutions held 94.39% of Quest Diagnostics' outstanding shares in their Q2 2026 13F filings, insiders about 0.43% based on their latest Form 4 filings, and other investors, including the public, the remaining 5.18%.
Over the trailing 12 months, 18 insiders reported transactions in DGX stock across 74 Form 4 filings.
The insider data for DGX reflects Form 4 filings through October 2, 2026.

Form 4 Holdings

Insiders Holding DGX

Insiders 23

Shares held 1.04Mn

Of outstanding 0.937%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Stephen H Rusckowski	Chairman, Ceo And President	389,597	389,597	37.5%	08 Mar, 2023
2	J. E. Davis	Ceo And President	122,423	122,423	11.8%	03 Sep, 2026
3	Mark Guinan	Executive Vice President Cfo	98,981	98,981	9.5%	09 Mar, 2022
4	Catherine T. Doherty	Evp, Regional Businesses	67,122	67,122	6.5%	06 Mar, 2026
5	Manner Carrie Eglinton	Svp, Advanced Diagnostics	48,391	48,391	4.7%	09 Mar, 2022
6	Michael E Prevoznik	Svp General Counsel	36,557	36,557	3.5%	31 Aug, 2026
7	Michael J Deppe	Svp, Corp. Controller Cao	35,196	35,196	3.4%	06 Mar, 2026
8	Sam Samad	Executive Vice President Cfo	33,478	33,478	3.2%	27 Jul, 2026
9	Timothy M Ring	Director	31,140	31,140	3.0%	21 May, 2026
10	Gary M Pfeiffer	Director	31,005	31,005	3.0%	21 May, 2026
11	Timothy L Main	Director	22,460	22,460	2.2%	27 Jul, 2026
12	Gail R Wilensky	Director	20,506	20,506	2.0%	19 May, 2023
13	Vicky B Gregg	Director	18,386	18,386	1.8%	27 Jul, 2026
14	Patrick Plewman	Svp For Diagnostic Services	15,293	15,293	1.5%	27 Jul, 2026
15	Karthik Kuppusamy	Svp, Clinical Solutions	13,557	13,557	1.3%	27 Jul, 2026
16	Denise M Morrison	Director	11,929	11,929	1.1%	21 May, 2026
17	Mark E Delaney	Svp Chief Commercial Officer	10,335	10,335	1.0%	29 Jul, 2026
18	Wright Iii Lassiter	Director	10,323	10,323	1.0%	27 Jul, 2026
19	Tracey Doi	Director	7,748	7,748	0.7%	21 May, 2026
20	Luis Diaz	Director	5,196	5,196	0.5%	21 May, 2026
21	Mark A Gardner	Svp Of Molecular Gen Oncol	4,673	4,673	0.4%	26 Sep, 2024
22	Robert B Carter	Director	3,864	3,864	0.4%	27 Jul, 2026
23	Timothy C Wentworth	Director	1,358	1,358	0.1%	21 May, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

2,728 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
01 Oct, 2026	Timothy C Wentworth	Director	Acquired A	135	$0.00	$0	477	Direct
01 Sep, 2026	J. E. Davis	Ceo And President	Disposed S	10,000	$242.72	$2.43Mn	122,423	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Acquired M	22,677	$112.17	$2.54Mn	60,234	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Disposed S	16,010	$242.88	$3.89Mn	44,224	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Disposed S	6,237	$243.63	$1.52Mn	37,987	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Disposed S	430	$244.51	$105.14K	37,557	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Disposed G	1,000	$0.00	$0	36,557	Direct
28 Aug, 2026	Michael E Prevoznik	Svp General Counsel	Disposed M	22,677	$112.17	$2.54Mn	0	Direct
28 Jul, 2026	Mark E Delaney	Svp Chief Commercial Officer	Disposed S	1,600	$235.18	$376.29K	10,335	Direct
22 Jul, 2026	Wright Iii Lassiter	Director	Acquired L	6	$206.81	$1.24K	10,323	Direct
22 Jul, 2026	Timothy L Main	Director	Acquired L	21	$206.81	$4.34K	22,460	Direct
22 Jul, 2026	Patrick Plewman	Svp For Diagnostic Services	Acquired L	46	$206.81	$9.51K	15,293	Direct
22 Jul, 2026	Robert B Carter	Director	Acquired L	11	$206.80	$2.27K	3,864	Direct
22 Jul, 2026	Vicky B Gregg	Director	Acquired A	72	$206.81	$14.89K	18,386	Direct
22 Jul, 2026	Mark E Delaney	Svp Chief Commercial Officer	Acquired L	34	$206.81	$7.03K	11,935	Direct
22 Jul, 2026	Sam Samad	Executive Vice President Cfo	Acquired A	102	$206.81	$21.09K	33,478	Direct
22 Jul, 2026	Karthik Kuppusamy	Svp, Clinical Solutions	Acquired L	37	$206.81	$7.65K	13,557	Direct
01 Jul, 2026	Timothy C Wentworth	Director	Acquired A	144	$0.00	$0	342	Direct
04 Jun, 2026	Karthik Kuppusamy	Svp, Clinical Solutions	Acquired M	3,320	$127.73	$424.05K	16,830	Direct
04 Jun, 2026	Karthik Kuppusamy	Svp, Clinical Solutions	Acquired M	4,827	$121.81	$587.95K	21,657	Direct

Showing 1 to 20 of 2,728 transactions